BioCatalystWatch
ADXNWorkspace / ADXN / OverviewCompany library
Addex Therapeutics Ltd. logo

Addex Therapeutics Ltd.

Addex Therapeutics Ltd. (ADXN)

Website

Price
Market cap
Next catalystLater in summer 2026NTX-253 · Phase 1 dataCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Other pipelines

ADX10059

mGluR5

PreINDP1P2P3FilingApproved
ADX10059

mGluR5

PreINDP1P2P3FilingApproved
ADX68692

PreINDP1P2P3FilingApproved

GABAB receptor

Dipraglurant

mGlu5

PreINDP1P2P3FilingApproved

PreINDP1P2P3FilingApproved
ADX71149

mGlu2

PreINDP1P2P3FilingApproved

Partner / License out

NTX-253

Muscarinic M4 receptor

PreINDP1P2P3FilingApproved
Upcoming / outlook

History / paused

ADX71149

mGlu2

PreINDP1P2P3FilingApproved

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Company funding outlook

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

ADXN SEC archive